{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:12:29Z","timestamp":1778595149482,"version":"3.51.4"},"reference-count":49,"publisher":"Baskent University","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.6002\/ect.2025.0309","type":"journal-issue","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:38:42Z","timestamp":1778492322000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Saadi MI, Tahmasebijaroubi F, Noshadi E, et al. Dysregulated expression of MiR-19b, MiR-25, MiR-17, WT1, and CEBPA in patients with acute myeloid leukemia and association with graft versus host disease after hematopoietic stem cell transplantation. South Asian J Cancer. 2022;11(4):346-352. doi:10.1055\/s-0042-1742593","DOI":"10.1055\/s-0042-1742593"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Khalafi-Nezhad A, Iravani Saadi M, Noshadi N, et al. Change in programmed death-1 and inducible costimulator expression in patients with acute myeloid leukemia following chemotherapy and its cytogenetic abnormalities. Galen Med J. 2022;11:e2394. doi:10.31661\/gmj.v11i.2394","DOI":"10.31661\/gmj.v11i.2394"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-1062. doi:10.1056\/NEJM199909303411407","DOI":"10.1056\/NEJM199909303411407"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Debnath A, Nath S. Prognosis and treatment in acute myeloid leukemia: a comprehensive review. Egypt J Med Human Genet. 2024;25(1):91. doi:10.1186\/s43042-024-00563-w","DOI":"10.1186\/s43042-024-00563-w"},{"key":"ref4","unstructured":"5. Shokouhi S, Bray S, Bakhtiyari S, Sayehmiri K, Alimoghadam K, Ghavamzadeh A. Effects of aGVHD and cGVHD on survival rate in patients with acute myeloid leukemia after allogeneic stem cell transplantation. Int J Hematol Oncol Stem Cell Res. 2015;9(3):112-121."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Bao H, Kolluri VK, Chen J, et al. Immune response in patients diagnosed with non-muscle invasive bladder cancer treated with CIMAvax-EGF concomitant with intravesical Bacillus Calmette-Guerin. J Cancer Sci Clin Therap. 2020;4(4):369-381. doi:10.26502\/jcsct.5079079","DOI":"10.26502\/jcsct.5079079"},{"key":"ref6","unstructured":"7. Saadi MI, Bozorgi H, Ramzi M, et al. Characterization of MiR-92b, 1275 and 551 in patients with acute myeloid leukemia and their association with acute graft versus host disease after hematopoietic stem cell transplantation. Int J Hemat Ther. 2020;6(1):1-6."},{"key":"ref7","unstructured":"8. Iravani Saadi M, Noshadi E, Aahmadyan M, et al. Expression of MiR-222 and MiR-15a in patients with transfusion-dependent thalassemia and its association with torque teno virus and cytomegalovirus infections. Heliyon. Available at SSRN: https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4177734"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. da Costa IB, de Melo AC, Callera F, Le\u00e3o MV. Biomarkers for graft-versus-host disease in hematopoietic stem cell transplant patients. Braz J Transplant. 2025;28:e1025. doi:10.53855\/bjt.v28i1.664_ENG","DOI":"10.53855\/bjt.v28i1.664_ENG"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Saadi MI, Hosseini F, Rostamipour HA, et al. Investigating apoptotic effect through blocking miR-181b and miR-222 using LNA-anti-miRNA in HL-60 cell line: strategies to improve hematopoietic stem cell transplantation. Int J Organ Transplant Med. 2024;15(1).","DOI":"10.61186\/ijotm.2024.15.1148"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Li S, Hu W, Qian L, Sun D. Insights into non-coding RNAS: biogenesis, function and their potential regulatory roles in acute kidney disease and chronic kidney disease. Mol Cell Biochem. 2025;480(3):1287-1304. doi:10.1007\/s11010-024-05083-0","DOI":"10.1007\/s11010-024-05083-0"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Wallace JA, O'Connell RM. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. Blood. 2017;130(11):1290-1301. doi:10.1182\/blood-2016-10-697698","DOI":"10.1182\/blood-2016-10-697698"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Marcucci G, Mrozek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011;117(4):1121-1129. doi:10.1182\/blood-2010-09-191312","DOI":"10.1182\/blood-2010-09-191312"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Weng H, Lal K, Yang FF, Chen J. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet. 2015;208(5):225-229. doi:10.1016\/j.cancergen.2014.12.006","DOI":"10.1016\/j.cancergen.2014.12.006"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Su R, Lin HS, Zhang XH, et al. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene. 2015;34(25):3226-3239. doi:10.1038\/onc.2014.274","DOI":"10.1038\/onc.2014.274"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Butrym A, Rybka J, Baczynska D, Poreba R, Mazur G, Kuliczkowski K. Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia. Oncol Lett. 2016;12(4):2296-2300. doi:10.3892\/ol.2016.4970","DOI":"10.3892\/ol.2016.4970"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Qiang P, Pan Q, Fang C, et al. MicroRNA-181a-3p as a diagnostic and prognostic biomarker for acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2020;12(1):e2020012. doi:10.4084\/MJHID.2020.012","DOI":"10.4084\/mjhid.2020.012"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A. 2008;105(10):3945-3950. doi:10.1073\/pnas.0800135105","DOI":"10.1073\/pnas.0800135105"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Cancer Genome Atlas Research N, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074. doi:10.1056\/NEJMoa1301689","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008;26(31):5078-5087. doi:10.1200\/JCO.2008.17.5554","DOI":"10.1200\/JCO.2008.17.5554"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1919-1928. doi:10.1056\/NEJMoa074256","DOI":"10.1056\/NEJMoa074256"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92(4):519-532. doi:10.3324\/haematol.11007","DOI":"10.3324\/haematol.11007"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136(15):1707-1721. doi:10.1182\/blood.2019004226","DOI":"10.1182\/blood.2019004226"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Sharma N, Liesveld JL. NPM 1 Mutations in AML-the landscape in 2023. Cancers (Basel). 2023;15(4). doi:10.3390\/cancers15041177","DOI":"10.3390\/cancers15041177"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Alpermann T, Schnittger S, Eder C, et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica. 2016;101(2):e55-58. doi:10.3324\/haematol.2015.133819","DOI":"10.3324\/haematol.2015.133819"},{"key":"ref25","unstructured":"26. Davoudi M, Davoodi P. Nucleophosmin 1 expression in acute myeloid leukemia. Rev Clin Med. 2015;2(4):209-211."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Hindley A, Catherwood MA, McMullin MF, Mills KI. Significance of NPM1 gene mutations in AML. Int J Molec Sc. 2021;22(18):10040. doi:10.3390\/ijms221810040","DOI":"10.3390\/ijms221810040"},{"key":"ref27","unstructured":"28. Koolivand M, Ansari M, Moein S, Afsa M, Malekzadeh K. The inhibitory effect of sulforaphane on the proliferation of acute myeloid leukemia cell lines through controlling miR-181a. Cell J. 2022;24(1):44-50. doi:10.22074\/cellj.2022.7508"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Saadi MI, Arandi N, Yaghobi R, Azarpira N, Geramizadeh B, Ramzi M. Up-regulation of the miR-92a and miR-181a in patients with acute myeloid leukemia and their inhibition with locked nucleic acid (LNA)-antimiRNA; introducing c-kit as a new target gene. Int J Hematol Oncol. 2018;35(3):238-247.","DOI":"10.4999\/uhod.183066"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Moassass F, Moualla Y, Al-Halabi B, Khamis A, Al-Achkar W. The clinical impact of NPM1 mutations and the effect of concurrent mutations in acute myeloid leukemia: unraveling the prognostic significance. Health Sci Rep. 2024;7(12):e70231. doi:10.1002\/hsr2.70231","DOI":"10.1002\/hsr2.70231"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Falini B, Sciabolacci S, Falini L, Brunetti L, Martelli MP. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. Leukemia. 2021;35(11):3113-3126. doi:10.1038\/s41375-021-01222-4","DOI":"10.1038\/s41375-021-01222-4"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Lu F, Zhang J, Ji M, et al. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol. 2014;45(1):383-392. doi:10.3892\/ijo.2014.2390","DOI":"10.3892\/ijo.2014.2390"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Lu H, Ding Y, Dong Y, et al. MicroRNA-181b-5p insufficiency predicts treatment response failure risk and unfavorable event-free survival as well as overall survival in acute myeloid leukemia patients. Oncol Lett. 2022;24(4):330. doi:10.3892\/ol.2022.13450","DOI":"10.3892\/ol.2022.13450"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Iravani Saadi M, Arandi N, Yaghobi R, Azarpira N, Geramizadeh B, Ramzi M. Aberrant expression of the miR-181b\/miR-222 after hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Indian J Hematol Blood Transfus. 2019;35(3):446-450. doi:10.1007\/s12288-018-01066-6","DOI":"10.1007\/s12288-018-01066-6"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Walker A, Marcucci G. Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Expert Rev Hematol. 2012;5(5):547-558. doi:10.1586\/ehm.12.45","DOI":"10.1586\/ehm.12.45"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Chandraprabha Vineetha R, Anitha Geetha Raj J, Devipriya P, Sreelatha Mahitha M, Hariharan S. MicroRNA-based therapies: revolutionizing the treatment of acute myeloid leukemia. Int J Lab Hematol. 2024;46(1):33-41. doi:10.1111\/ijlh.14211","DOI":"10.1111\/ijlh.14211"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Sang W, Zhang C, Zhang D, et al. MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-gamma production. Am J Hematol. 2015;90(11):998-1007. doi:10.1002\/ajh.24136","DOI":"10.1002\/ajh.24136"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(36):5257-5264. doi:10.1200\/JCO.2010.29.2953","DOI":"10.1200\/JCO.2010.29.2953"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Al Hamed R, Labopin M, Daguindau E, et al. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia. Cancer Med. 2022;11(4):1068-1080. doi:10.1002\/cam4.4218","DOI":"10.1002\/cam4.4218"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Karas M, Steinerova K, Lysak D, et al. Pre-transplant quantitative determination of NPM1 mutation significantly predicts outcome of allogeneic hematopoietic stem cell transplantation in patients with normal karyotype AML in complete remission. Anticancer Res. 2016;36(10):5487-5498. doi:10.21873\/anticanres.11130","DOI":"10.21873\/anticanres.11130"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. Xian J, Shao H, Chen X, et al. Nucleophosmin mutants promote adhesion, migration and invasion of human leukemia THP-1 cells through MMPs up-regulation via Ras\/ERK MAPK signaling. Int J Biol Sci. 2016;12(2):144-155. doi:10.7150\/ijbs.13382","DOI":"10.7150\/ijbs.13382"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Wang R, Xu P, Chang LL, Zhang SZ, Zhu HH. Targeted therapy in NPM1-mutated AML: knowns and unknowns. Front Oncol. 2022;12:972606. doi:10.3389\/fonc.2022.972606","DOI":"10.3389\/fonc.2022.972606"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43. Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109-1120. doi:10.1182\/blood-2010-08-299990","DOI":"10.1182\/blood-2010-08-299990"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44. Khan I, Kaempf A, Raghuwanshi S, et al. Favorable outcomes of NPM1(mut) AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance. Blood Cancer J. 2023;13(1):128. doi:10.1038\/s41408-023-00898-4","DOI":"10.1038\/s41408-023-00898-4"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45. Falini B, Dillon R. Criteria for diagnosis and molecular monitoring of NPM1-mutated AML. Blood Cancer Discov. 2024;5(1):8-20. doi:10.1158\/2643-3230.BCD-23-0144","DOI":"10.1158\/2643-3230.BCD-23-0144"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46. Mer AS, Heath EM, Madani Tonekaboni SA, et al. Biological and therapeutic implications of a unique subtype of NPM1 mutated AML. Nat Commun. 2021;12(1):1054. doi:10.1038\/s41467-021-21233-0","DOI":"10.1038\/s41467-021-21233-0"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47. Haferlach T, Kohlmann A, Schnittger S, et al. AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer. 2005;43(2):113-127. doi:10.1002\/gcc.20175","DOI":"10.1002\/gcc.20175"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48. Dohner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program. 2011;2011:36-42. doi:10.1182\/asheducation-2011.1.36","DOI":"10.1182\/asheducation-2011.1.36"},{"key":"ref48","unstructured":"49. Sohrabi T, Ayatollahi H, Rokni M, et al. Correlation of BCRP expression to NPM1 mutations in acute myeloid leukemia. Int J Hemat Oncol. 2018;35(2):186-186."}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:10:32Z","timestamp":1778591432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2026\/24\/4\/0\/343\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2025.0309","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}